Uveitis refers to several ocular disorders characterized by intraocular inflammation, and in the aggregate, are major causes of visual loss and blindness in the United States. Because the peak onset of uveitis is in young adulthood, vision loss due to uveitis has a disproportionately greater impact on years of potential vision lost per case than age-related eye diseases. Most of the diseases causing uveitis are chronic and require long-term therapy. Current therapy for patients with severe, vision-threatening uveitis typically involves the use of systemic medications, primarily oral corticosteroids, and supplemented by immunosuppressive drugs in selected situations. The fluocinolone acetonide intraocular implant is a recently developed, surgically implanted reservoir of corticosteroid designed to last three years and to provide long-term control of uveitis. A multicenter, randomized controlled clinical trial, the Multicenter Uveitis Steroid Treatment (MUST) trial, is proposed, which will compare the fluocinolone acetonide implant to """"""""standard therapy"""""""" for the treatment of patients with severe, vision-threatening intermediate, posterior, or panuveitis. Patients with active uveitis will be randomized to treatment with either the fluocinolone acetonide implant or """"""""standard therapy"""""""" consisting of oral corticosteroids. The design outcome will be visual impairment after two years of treatment; other outcomes include ability to control the uveitis, resolution of macular edema, and ocular and systemic morbidity from both the disease and treatments. Additional benefits include prospective epidemiologic data on the long-term outcomes of uveitis, its complications, treatments, and their complication. This application is for the establishment of a Coordinating Center (CC) for the MUST trial and is submitted in conjunction with applications for the Chairman's Office and the Reading Center. The primary responsibilities of the CC are to: (1) establish and maintain the clinical center research network; (2) provide comprehensive information management systems for MUST including a distributed data system and a study web-site; (3) develop and maintain study documentation, including protocol, handbook, and data collection forms; and (4) assemble, analyze and report data on study performance and trial results. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10EY014660-02
Application #
6922760
Study Section
Special Emphasis Panel (ZEY1-VSN (09))
Program Officer
Kurinij, Natalie
Project Start
2004-07-15
Project End
2009-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
2
Fiscal Year
2005
Total Cost
$1,793,111
Indirect Cost
Name
Johns Hopkins University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Seemiller, Eric S; Port, Nicholas L; Candy, T Rowan (2018) The gaze stability of 4- to 10-week-old human infants. J Vis 18:15
Sugar, Elizabeth A; Venugopal, Vidya; Thorne, Jennifer E et al. (2017) Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy. Ophthalmology 124:1662-1669
Sen, H Nida; Abreu, Francis M; Louis, Thomas A et al. (2016) Cataract Surgery Outcomes in Uveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology 123:183-90
Holbrook, Janet T; Sugar, Elizabeth A; Burke, Alyce E et al. (2016) Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Am J Ophthalmol 164:29-36
Altaweel, Michael M; Gangaputra, Sapna S; Thorne, Jennifer E et al. (2016) Morphological assessment of the retina in uveitis. J Ophthalmic Inflamm Infect 6:33
Yu, Tsung; Holbrook, Janet T; Thorne, Jennifer E et al. (2016) Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis. Pharmacoepidemiol Drug Saf 25:363-71
Kempen, John H; Van Natta, Mark L; Altaweel, Michael M et al. (2015) Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. Am J Ophthalmol 160:1133-1141.e9
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Kempen, John H; Altaweel, Michael M et al. (2015) Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Ophthalmology 122:1967-75
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group (2015) Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatmen Ophthalmology 122:1976-86
Yu, Tsung; Holbrook, Janet T; Thorne, Jennifer E et al. (2015) Outcome Preferences in Patients With Noninfectious Uveitis: Results of a Best-Worst Scaling Study. Invest Ophthalmol Vis Sci 56:6864-72

Showing the most recent 10 out of 27 publications